Alnylam Pharmaceuticals Inc (0HD2)
LSE
236.70
+3.84 (+1.65%)
Real-time Data
07:00 AM
Day's Range
226.00240.00
52 wk Range
199.81500.21
Financial Statements - 0HD2 - Alnylam Pharmaceuticals Inc
Revenue
5.71T▲ 43.7%
Net Income
1.55T▲ 38.5%Net Margin 27.1%
EBITDA
2.12T▲ 49.1%
Free Cash Flow
2.10T▲ 95.4%
Income Statement
| Period Ending | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|
| Sales | 5.71T | 3.97T | 7.20T | 7.08T |
| Cost of Goods | 2.94T | 2.03T | 3.14T | 3.03T |
| Gross Profit | 2.76T | 1.94T | 4.05T | 4.05T |
 Operating Expense | - | - | - | - |
| Operating Income | 2.26T | 1.50T | 3.45T | 3.45T |
| Non-Operating Interest | - | - | - | - |
| Other Income Expense | - | - | - | - |
| Pre Tax Income | 1.56T | 1.14T | 3.27T | 2.85T |
| Income Tax | 13.81B | 29.86B | 30.90B | 26.94B |
| Net Income | 1.55T | 1.11T | 3.23T | 2.82T |
| EPS Basic | 28.71 | 19.31 | 56.47 | 52.8 |
| EPS Diluted | 28.71 | 19.31 | 56.47 | 52.8 |
| Basic Shares Outstanding | 48.15B | 48.15B | 48.15B | 48.15B |
| Diluted Shares Outstanding | 48.15B | 48.15B | 48.15B | 48.15B |
| Ebit | - | - | - | - |
| Ebitda | 2.12T | 1.42T | 3.50T | 3.14T |
| Net Income Continuous Operations | - | - | - | - |
| Minority Interests | -167.88B | -189.19B | -520.26B | -284.06B |
| Preferred Stock Dividends | 0 | 0 | 0 | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
